To include your compound in the COVID-19 Resource Center, submit it here.

ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE